Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.
The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.
Patients with ER-positive, triple-negative metastatic breast cancer treated with a HER3-direct antibody drug conjugate obtained clinical responses with a positive safety profile.
The addition of the soluble LAG-3 protein eftilagimod alpha to pembrolizumab produced responses and was well tolerated in patients with metastatic head and neck squamous cell carcinoma.
The LAG-3 inhibitor fianlimab plus cemiplimab produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study.